phosphonoacetic acid has been researched along with Breast Neoplasms in 13 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cultured wild-type MCF-7 human breast cancer cells and two MCF-7 sublines that overproduce enzymes of the de novo pyrimidine biosynthetic pathway were compared with regard to: rate of de novo biosynthesis of uracil nucleotides, sensitivity of the de novo and salvage pathways to the concentration of intracellular uracil nucleotides, and potential of exogenous uridine at concentrations equivalent to plasma levels to affect de novo pyrimidine biosynthesis." | 3.67 | Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the de novo pyrimidine pathway. ( Chisena, CA; Cowan, KH; Cysyk, RL; Karle, JM, 1986) |
| "Four of ten patients with colorectal cancer responded to the treatment (four partial responses), of whom three had been treated previously." | 2.67 | A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. ( Ardalan, B; Benedetto, P; Feun, L; Fodor, M; Livingstone, A; Morrell, L; Richman, S; Savaraj, N; Sridhar, KS; Waldman, S, 1991) |
| "Sixty-three patients with Stage IV breast carcinoma refractory to standard combination chemotherapy agents such as 5-fluorouracil (5-FU) were entered into a study to determine the efficacy of a multiple dose schedule of N-(phosphonacetyl)-L-aspartic acid (PALA) and whether the addition of PALA improves the therapeutic efficacy of 5-FU." | 2.66 | A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer. ( Buzdar, AU; Hortobagyi, GN; Mann, GB; Valdivieso, M; Yap, HY, 1985) |
| "One of the responding patients with colon cancer and two with breast cancer had failed to respond to prior therapy with 5-FU; one of the responding patients with breast cancer had previously received an inadequate trial of a similar regimen." | 1.26 | Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU. ( Ervin, TJ; Kufe, DW; Meshad, MW; Weiss, GR, 1982) |
| "Thirty-three patients with advanced breast cancer were treated with PALA at a schedule of 1500 mg/m2/day for 5 days every 3 weeks." | 1.26 | PALA in advanced breast cancer. A phase II pilot study by the ECOG. ( Davis, TE; Falkson, G; Keller, AM; Taylor, SG, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (53.85) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lacerda-Abreu, MA | 1 |
| Russo-Abrahão, T | 1 |
| Cosentino-Gomes, D | 1 |
| Nascimento, MTC | 1 |
| Carvalho-Kelly, LF | 1 |
| Gomes, T | 1 |
| Rodrigues, MF | 1 |
| König, S | 1 |
| Rumjanek, FD | 1 |
| Monteiro, RQ | 1 |
| Meyer-Fernandes, JR | 1 |
| Ying, H | 1 |
| Subrata, S | 1 |
| Paridaens, R | 1 |
| Mouridsen, HT | 1 |
| Palshof, T | 1 |
| Cocconi, G | 1 |
| Van Oosterom, A | 1 |
| Rotmensz, N | 1 |
| Sylvester, R | 1 |
| Heuson, JC | 1 |
| Rozencweig, M | 1 |
| Ardalan, B | 3 |
| Jamin, D | 1 |
| Jayaram, HN | 2 |
| Presant, CA | 1 |
| Weiss, GR | 1 |
| Ervin, TJ | 1 |
| Meshad, MW | 1 |
| Kufe, DW | 1 |
| Taylor, SG | 1 |
| Davis, TE | 1 |
| Falkson, G | 1 |
| Keller, AM | 1 |
| Glazer, RI | 1 |
| Kensler, TW | 1 |
| Van Pham, T | 1 |
| Macdonald, JS | 1 |
| Cooney, DA | 1 |
| Gudas, JM | 1 |
| Nguyen, H | 1 |
| Li, T | 1 |
| Sadzewicz, L | 1 |
| Robey, R | 1 |
| Wosikowski, K | 1 |
| Cowan, KH | 2 |
| Santos, O | 1 |
| Pant, KD | 1 |
| Blank, EW | 1 |
| Ceriani, RL | 1 |
| Sridhar, KS | 1 |
| Benedetto, P | 1 |
| Richman, S | 1 |
| Waldman, S | 1 |
| Morrell, L | 1 |
| Feun, L | 1 |
| Savaraj, N | 1 |
| Fodor, M | 1 |
| Livingstone, A | 1 |
| Allegra, CJ | 1 |
| Karle, JM | 1 |
| Chisena, CA | 1 |
| Cysyk, RL | 1 |
| Mann, GB | 1 |
| Hortobagyi, GN | 1 |
| Buzdar, AU | 1 |
| Yap, HY | 1 |
| Valdivieso, M | 1 |
2 trials available for phosphonoacetic acid and Breast Neoplasms
| Article | Year |
|---|---|
A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; B | 1991 |
A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Breast Neoplasms; Female | 1985 |
11 other studies available for phosphonoacetic acid and Breast Neoplasms
| Article | Year |
|---|---|
H
Topics: Breast Neoplasms; Cadherins; Cell Adhesion; Cell Line; Cell Proliferation; Down-Regulation; Female; | 2019 |
[S-phase arrest associated apoptosis leads to diversities of drug resistance and mutation rate in human breast cancer cells].
Topics: Antineoplastic Agents; Apoptosis; Aspartic Acid; Breast Neoplasms; Drug Resistance, Neoplasm; Humans | 1999 |
N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Breast Neoplasms; Digestive System; Dru | 1982 |
Phase I study of continuous-infusion PALA and 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Asparti | 1984 |
Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU.
Topics: Adult; Aged; Aspartic Acid; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Drug Evaluation; Drug Th | 1982 |
PALA in advanced breast cancer. A phase II pilot study by the ECOG.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Bone Marrow; Breast Neoplasms; Digestive System; | 1982 |
Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-L-aspartate on cell growth and ribonucleic acid synthesis in human mammary carcinoma.
Topics: Antineoplastic Agents; Aspartic Acid; Breast Neoplasms; Cell Division; Cell Line; Drug Synergism; Fe | 1981 |
Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein.
Topics: Amides; Antineoplastic Agents; Aspartic Acid; Blotting, Western; Breast Neoplasms; Cell Cycle; Clone | 1996 |
5-Iododeoxyuridine increases the efficacy of the radioimmunotherapy of human tumors growing in nude mice.
Topics: Animals; Aspartic Acid; Breast Neoplasms; Deoxycytidine; Drug Therapy, Combination; Humans; Idoxurid | 1992 |
Biochemical modulation: a modality that has come of therapeutic age.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Brea | 1991 |
Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the de novo pyrimidine pathway.
Topics: Amides; Aspartate Carbamoyltransferase; Aspartic Acid; Breast Neoplasms; Carbamoyl-Phosphate Synthas | 1986 |